News
A first-in-human trial of Arvinas’ investigational Parkinson’s’ disease therapy, ARV-102, has been able to demonstrate a drop in the multifunctional protein that has been associated with the ...
First PROTAC Drug Is Expected To Enter Market By 2027 Says Kuick Research In Its Latest Published Report On PROTA Drugs Clinical Trials & Market OpportunityDelhi, Oct. 14, 2024 (GLOBE NEWSWIRE ...
The PROTAC candidates “… demonstrate potent antiretroviral activity in HIV-infected primary cells, supporting further development for testing in the context of HIV-1 reservoir reduction in ...
ARV-102 is an oral, brain-penetrant investigational PROTAC designed to degrade leucine-rich repeat kinase 2 (LRRK2), which is a large, multidomain scaffolding kinase.
Vepdegestrant is an oral proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader that directly harnesses the ubiquitin–proteasome system.In this phase 3, open-label, randomized ...
Poster title: ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, combined with biologics or small-molecule inhibitors induces tumor regressions in diffuse large B-Cell lymphoma models.
Pfizer, Arvinas post mixed breast cancer survival results in first phase 3 test for a PROTAC degrader. By James Waldron Mar 11, 2025 10:06am. Pfizer Arvinas breast cancer PROTAC. Pfizer and ...
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress. News provided by. Arvinas Inc. Jun 13, 2025 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results